Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Echinaforce COVID-19 Shedding Study
NCT04999098Phase 4Terminated
- Sponsor
- A.Vogel
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of echinacea purpurea extract in coronavirus disease 2019 (COVID-19), sponsored by A.Vogel. Primary endpoint: Absolute and relative differences in Cq values (qPCR) comparing pre- and post EF treatment at 2 hours. Started Nov 2021; status: terminated.
02
Drugs
echinacea purpurea extract
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04999098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999098.